A study to assess efficacy and safety of low-dose anti-PD1 antibodies (Pembrolizumab or Nivolumab) in patients with relapsed/refractory classical Hodgkin lymphoma
Latest Information Update: 28 Jan 2021
At a glance
- Drugs Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Hodgkin's disease
- Focus Adverse reactions; Therapeutic Use
- 28 Jan 2021 New trial record
- 01 Dec 2020 Results (n=17) published in the Hematological Oncology